The availability of medications for opioid use disorder (MOUD) has increased—but still doesn’t reflect the availability of medications for other health conditions. About 45% of opioid treatment programs (OTPs) offer all three approved medications for opioid use disorder (MOUD)—methadone, buprenorphine, and naltrexone – according to a recent report, Availability Of Medications For Opioid Use Disorder In Opioid Treatment Programs. The percentage of OTPs offering the full range of MOUD increased from 33% in 2017, but uptake of buprenorphine and naltrexone has been uneven.

All the OTPs surveyed offer methadone. The percentage of OTPs offering buprenorphine increased from 67.0% in 2017 to 85.1% in 2023. The percentage of OTPs offering naltrexone increased from 38.2% in 2017 to 52.7% in 2023 (see …